Spots Global Cancer Trial Database for pten
Every month we try and update this database with for pten cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations | NCT02461446 | PTEN ASD Autism Macrocephaly PTEN Hamartoma ... | 18 Months - | Boston Children's Hospital | ||
| Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) | NCT02761694 | Cancer Solid Tumors | Vevorisertib Fulvestrant Paclitaxel | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Development and Validation of an Online Neurobehavioral Evaluation Tool for PTEN Patients | NCT05671107 | PTEN Hamartoma ... | NET | 3 Years - 45 Years | John Carroll University | |
| A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi | NCT01633060 | Metastatic Brea... | Fulvestrant BKM120 BKM120 matching... | 18 Years - | Novartis | |
| Response of Immune System to Flu Vaccination in PHTS | NCT03630523 | PTEN Hamartoma ... | Influvac Tetra | 18 Years - | Radboud University Medical Center | |
| TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations | NCT04770246 | Advanced or Met... Advanced or Met... | TAS-117 TAS-117 TAS-117 TAS-117 | 12 Years - | Taiho Oncology, Inc. | |
| PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion | NCT00173407 | Ovarian Cancer | immunohistochem... | 21 Years - 80 Years | National Taiwan University Hospital | |
| Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab. | NCT01068132 | Colorectal Canc... | Cetuximab FOLFIRI | 18 Years - 80 Years | Regione Lombardia | |
| RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome | NCT02991807 | PTEN Gene Mutat... PTEN Hamartoma ... | RAD001 Placebo | 5 Years - 45 Years | Boston Children's Hospital | |
| Benign Reproductive Tissue Analysis for Endometrial Cancer Markers | NCT00481754 | Oophorectomy fo... Hysterectomy | 18 Years - 54 Years | National Institutes of Health Clinical Center (CC) | ||
| Sirolimus for Cowden Syndrome With Colon Polyposis | NCT04094675 | PTEN Gene Mutat... PTEN Hamartoma ... PTEN Hamartoma ... Cowden Syndrome Bannayan Syndro... Bannayan Zonana... Polyposis | Sirolimus | 18 Years - 80 Years | Ohio State University | |
| Sulphate Accumulation in Prostate | NCT02821728 | Prostate Cancer | Dietary interve... Normal diet | 18 Years - 80 Years | Quadram Institute Bioscience | |
| Sirolimus for Cowden Syndrome With Colon Polyposis | NCT04094675 | PTEN Gene Mutat... PTEN Hamartoma ... PTEN Hamartoma ... Cowden Syndrome Bannayan Syndro... Bannayan Zonana... Polyposis | Sirolimus | 18 Years - 80 Years | Ohio State University | |
| TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations | NCT04770246 | Advanced or Met... Advanced or Met... | TAS-117 TAS-117 TAS-117 TAS-117 | 12 Years - | Taiho Oncology, Inc. | |
| TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations | NCT04770246 | Advanced or Met... Advanced or Met... | TAS-117 TAS-117 TAS-117 TAS-117 | 12 Years - | Taiho Oncology, Inc. | |
| A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation | NCT01572727 | Breast Cancer | Paclitaxel BKM120 matching... BKM120 | 18 Years - | Novartis | |
| Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer | NCT01514565 | Breast Cancer | 18 Years - | Thomas Jefferson University | ||
| Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency | NCT04493853 | Hormone-Sensiti... | Capivasertib Placebo Abiraterone Ace... | 18 Years - 130 Years | AstraZeneca | |
| Benign Reproductive Tissue Analysis for Endometrial Cancer Markers | NCT00481754 | Oophorectomy fo... Hysterectomy | 18 Years - 54 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
